Verastem (VSTM) Competitors

Verastem logo
$6.11 +0.03 (+0.49%)
Closing price 02/13/2025 04:00 PM Eastern
Extended Trading
$6.02 -0.09 (-1.39%)
As of 02/13/2025 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VSTM vs. EBS, RIGL, CDXS, IRWD, XOMA, VNDA, SGMO, LXRX, ACHV, and AGEN

Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.

Verastem vs.

Emergent BioSolutions (NYSE:EBS) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Verastem has a net margin of 0.00% compared to Emergent BioSolutions' net margin of -18.55%. Emergent BioSolutions' return on equity of -9.91% beat Verastem's return on equity.

Company Net Margins Return on Equity Return on Assets
Emergent BioSolutions-18.55% -9.91% -3.31%
Verastem N/A -332.73%-73.97%

Emergent BioSolutions currently has a consensus price target of $14.33, suggesting a potential upside of 51.44%. Verastem has a consensus price target of $13.63, suggesting a potential upside of 123.00%. Given Verastem's higher possible upside, analysts plainly believe Verastem is more favorable than Emergent BioSolutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emergent BioSolutions
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verastem
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Emergent BioSolutions had 4 more articles in the media than Verastem. MarketBeat recorded 4 mentions for Emergent BioSolutions and 0 mentions for Verastem. Emergent BioSolutions' average media sentiment score of 0.66 beat Verastem's score of 0.00 indicating that Emergent BioSolutions is being referred to more favorably in the media.

Company Overall Sentiment
Emergent BioSolutions Positive
Verastem Neutral

Verastem received 188 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.72% of users gave Emergent BioSolutions an outperform vote while only 65.28% of users gave Verastem an outperform vote.

CompanyUnderperformOutperform
Emergent BioSolutionsOutperform Votes
425
66.72%
Underperform Votes
212
33.28%
VerastemOutperform Votes
613
65.28%
Underperform Votes
326
34.72%

Emergent BioSolutions has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Verastem has lower revenue, but higher earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emergent BioSolutions$1.05B0.49-$760.50M-$4.10-2.31
Verastem$2.60M104.60-$87.37M-$3.19-1.92

78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by insiders. Comparatively, 2.2% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Verastem beats Emergent BioSolutions on 10 of the 17 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VSTM vs. The Competition

MetricVerastemPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$271.96M$6.93B$5.81B$9.15B
Dividend YieldN/A2.91%5.29%4.00%
P/E Ratio-1.929.8526.0719.43
Price / Sales104.60251.71446.4071.49
Price / CashN/A75.4646.0938.87
Price / Book2.695.577.415.07
Net Income-$87.37M$123.72M$3.19B$222.90M
7 Day Performance5.53%-0.11%0.92%1.23%
1 Month Performance21.23%2.71%4.83%4.23%
1 Year Performance-48.48%3.56%23.85%20.29%

Verastem Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VSTM
Verastem
2.9854 of 5 stars
$6.11
+0.5%
$13.63
+123.0%
-48.0%$271.96M$2.60M-1.9250
EBS
Emergent BioSolutions
4.3293 of 5 stars
$10.50
-6.7%
$14.33
+36.5%
+495.3%$568.78M$1.05B-2.561,600Gap Down
RIGL
Rigel Pharmaceuticals
3.2108 of 5 stars
$21.16
-2.3%
$36.20
+71.1%
+86.3%$372.73M$157.47M151.15160Short Interest ↑
Gap Down
CDXS
Codexis
3.8614 of 5 stars
$4.27
+1.9%
$8.33
+95.2%
+51.0%$347.49M$70.14M-4.91250News Coverage
IRWD
Ironwood Pharmaceuticals
4.3727 of 5 stars
$2.10
-10.3%
$10.67
+407.9%
-86.8%$336.06M$442.73M-70.00220Upcoming Earnings
Insider Trade
Short Interest ↑
XOMA
XOMA
4.544 of 5 stars
$24.88
-6.5%
$72.00
+189.4%
+38.6%$293.09M$4.76M-7.1510Analyst Upgrade
VNDA
Vanda Pharmaceuticals
4.1261 of 5 stars
$4.31
-2.3%
$15.50
+259.6%
+15.8%$251.32M$192.64M-15.39290Earnings Report
News Coverage
SGMO
Sangamo Therapeutics
1.4878 of 5 stars
$1.17
-4.9%
$5.17
+341.6%
+74.6%$244.12M$52.29M-1.56480Gap Up
LXRX
Lexicon Pharmaceuticals
1.6208 of 5 stars
$0.73
-3.8%
$5.00
+587.4%
-74.7%$179.12M$1.20M-0.97140Gap Up
ACHV
Achieve Life Sciences
2.3867 of 5 stars
$3.26
-0.3%
$14.80
+354.0%
-24.2%$112.11MN/A-2.8820Short Interest ↓
Gap Up
AGEN
Agenus
3.8201 of 5 stars
$3.51
-7.6%
$10.00
+184.9%
-77.0%$82.35M$156.31M-0.31440Gap Down

Related Companies and Tools


This page (NASDAQ:VSTM) was last updated on 2/14/2025 by MarketBeat.com Staff
From Our Partners